Abstract
A hallmark of α-synucleinopathies (e.g., Parkinson’s disease) is the misfolding and aggregation of α-synuclein in tissues and biological fluids. Protein amplification assays like real-time quaking-induced conversion (RT-QuIC) are sensitive yet currently limited to semi-invasive sample types such as cerebrospinal fluid because more accessible samples, such as blood, contain inhibitors. Here, we show that Nanoparticle-enhanced Quaking-induced Conversion (Nano-QuIC) can double the speed of reactions spiked with misfolded α-synuclein while increasing sensitivity 100-fold in human plasma. Nano-QuIC detected spike concentrations down to 90 pg/mL in lysed whole blood, while reactions without nanoparticles (RT-QuIC) failed to have any detection due to the presence of strong inhibitors. Moreover, Nano-QuIC showed increased seeding activity in plasma samples from Parkinson’s patients (n = 4) versus healthy controls (n = 4). This sets the groundwork for the noninvasive diagnostic use of Nano-QuIC, potentially enabling early disease detection and management through blood-based testing.
Original language | English (US) |
---|---|
Pages (from-to) | 15016-15024 |
Number of pages | 9 |
Journal | Nano letters |
Volume | 24 |
Issue number | 47 |
DOIs | |
State | Published - Nov 27 2024 |
Bibliographical note
Publisher Copyright:© 2024 American Chemical Society.
Keywords
- Nanoparticle-enhanced Quaking-induced Conversion (Nano-QuIC)
- Parkinson’s disease
- disease diagnostics
- real-time quaking-induced conversion (RT-QuIC)
- seeded amplification assay (SAA)
- α-synuclein
PubMed: MeSH publication types
- Journal Article